Experimental pill promises new hope for deadly pancreatic cancer
The once-daily pill caused fewer severe side effects and may become a new standard of care, researchers said.
- On Sunday at the American Society for Clinical Oncology meeting in Chicago, researchers reported that the experimental pill daraxonrasib nearly doubled survival times for patients with advanced pancreatic cancer compared to chemotherapy.
- The drug targets the mutated KRAS gene, found in more than 90 per cent of pancreatic tumours, which continuously signals cancer cells to grow and was long considered 'undruggable' by researchers.
- In the 500-patient trial, daraxonrasib recipients lived a median of 13.2 months versus 6.7 months for chemotherapy patients, with severe side effects in 43.6 per cent of cases compared to 57.5 per cent on chemotherapy.
- Dr. Rachna Shroff of the Arizona Cancer Center called the results 'landscape-changing,' while the Food and Drug Administration plans to expedite review of the drug as a potential new standard of care.
- Researchers are now exploring whether daraxonrasib might shrink tumors to allow for surgery in earlier-stage patients, while the agency currently allows 'expanded access' to the experimental treatment for patients meeting specific criteria.
145 Articles
145 Articles
New pancreatic cancer pill may revolutionize treatment for the deadly disease, experts say
Pancreatic cancer patients who received he experimental drug daraxonrasib during a clinical trial lived twice as long as those who received chemotherapy, researchers found. The drug may revolutionize pancreatic cancer treatment, they say.
New Drug Doubles Survival Time For Pancreatic Cancer Patients
Could a single daily pill finally change the outlook for one of the deadliest cancers in the world? Scientists believe a new drug may have done just that.Researchers say a treatment called daraxonrasib has nearly doubled survival times for patients with advanced pancreatic cancer. Offering fresh hope against a disease that has long been among the hardest to treatThe international trial, involving 500 patients across North America, Europe, and As…
Pill offers hope in treating deadly pancreatic cancer
What happenedA cancer drug decades in the making significantly extended and improved the life of patients whose metastatic pancreatic cancer had stopped responding to previous treatments, researchers reported Sunday in The New England Journal of Medicine and at an American Society for Clinical Oncology meeting in Chicago. In a study of 500 last-stage pancreatic patients, those assigned Revolution Medicine’s daraxonrasib pill lived an average of …
A new drug could fundamentally change the treatment of pancreatic cancer: in a phase III study, patients lived twice as long as patients who received standard chemotherapy.
Coverage Details
Bias Distribution
- 49% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
